Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Drug Survival of Dupilumab Affected by Immunosuppressive Therapy, Older Age in AD

August 18th 2022, 12:10pm


Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.

Race, Insurance Type Among Predictors of Depressive Symptoms in Atopic Dermatitis

August 10th 2022, 6:40pm


Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.

Investigating Patient Preferences for Atopic Dermatitis Treatment

August 8th 2022, 6:40pm


European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy.

Exploring Clinical, Diagnostic Features of Photoaggravated Atopic Dermatitis

August 2nd 2022, 1:20pm


Substantially impaired quality of life was shown in patients with photoaggravated atopic dermatitis, with phototesting cited as an effective diagnostic approach in promoting personalized care.

Overuse of Systemic Corticosteroids, Substantial Cost Burden for AD Seen in Germany

July 29th 2022, 3:20pm


Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.

Dr Elaine Siegfried Discusses Step Edits, Barriers to AD Treatment

July 23rd 2022, 12:10pm


Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on step edits and other barriers limiting access to biologic, topical, and other medications for the treatment of atopic dermatitis (AD).

Examining the Impact of Atopic Dermatitis Severity on Families of Pediatric Patients

July 20th 2022, 6:40pm


Increased atopic dermatitis severity in pediatric patients was associated with a greater physical, emotional, social, and economic impact on families.

Itch and Skin Pain in Patients With AD Linked With Significant QOL Burden

July 11th 2022, 5:40pm


The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs.

Disease Severity, Time Managing Symptoms Contribute to High Disease Burden for Patients With AD

July 6th 2022, 3:06pm


A majority of patients with moderate or severe atopic dermatitis (AD) reported moderate-to-high negative impacts on quality of life.

Dr Elaine Siegfried on Preventive Strategies to Reduce Comorbidity Risk in Atopic Dermatitis

July 2nd 2022, 2:35pm


Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, addresses the comorbidity profile associated with atopic dermatitis and the utility of disease-modifying drugs to reduce risk of comorbid conditions.